Roche launches "future proof" Chlamydia test in Europe
This article was originally published in Clinica
Roche Diagnostics has launched its Cobas TaqMan CT Test v2.0 in Europe. It CE marked the diagnostic, for detecting Chlamydia trachomatis, in June. Basel, Switzerland-based Roche claims the test is "future-proof", meaning it still produces reliable results even when mutations occur in the bacteria's cryptic plasmid DNA. It does this by simultaneously detecting two targets within the C trachomatis cryptic plasmid and genome target DNA. Plasmids are outside a bacteria's chromosomal DNA and are capable of replicating independently. The test is run on the Cobas TaqMan 48 analyser, which can carry out 48 tests per run with results available in 2.5 hours.